Neuren announces new US patent to be granted for NNZ-2591

1 of 2 Neuren (NEU) - ASX Announcement 5 December 2017 New US patent to be granted for Neuren’s NNZ-2591 Melbourne, Australia, 5 December 2017: Neuren Pharmaceuticals (ASX: NEU) today announced that the US Patent and Trademark Office has issued a Notice of Allowance of a new patent for NNZ-2591, which is expected to expire in July 2034. The patent (application number 15/004,218) concerns a method for treating an autism spectrum disorder or neurodevelopmental disorder using cyclic glycyl-2-allyl proline (NNZ-2591). Similar applications are pending in Europe and Japan. The new patent will supplement composition of matter patents in the US, Europe and Japan which have been granted until 2024, with the potential to extend expiry to 2029. NNZ-2591 is a synthetic analog of the neurotrophic peptide cyclic glycine proline (cGP), which occurs naturally in the brain. NNZ-2591 has demonstrated efficacy in pre-clinical models of Parkinson’s disease, stroke, traumatic brain injury, peripheral neuropathy, Fragile X syndrome, memory impairment and multiple sclerosis. cGP has been shown to regulate the binding of IGF-1 to IGF Binding Protein 3 in the brain. An abnormally high amount of IGF Binding Protein 3 is a feature of Rett syndrome. Neuren also confirmed that validation of the recently granted patent concerning the use of its lead molecule trofinetide to treat autism spectrum disorders has now been completed in all the member states of the European Patent Organisation. The patents in each country expire in 2032. Neuren Executive Chairman Richard Treagus commented: “This new patent will further strengthen the robust commercial exclusivity that has been put in place for both trofinetide and NNZ-2591, through a combination of composition of matter patents, method patents and orphan drug exclusivity periods.” About Neuren Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company developing new therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Neuren presently has trofinetide in Phase 2 clinical trials as well as NNZ-2591 in pre-clinical development. Trofinetide is a synthetic analogue of a naturally occurring neurotrophic peptide derived from IGF-1, a growth factor produced by brain cells. In animal models, trofinetide exhibits a wide range of important effects including inhibiting neuroinflammation, normalizing the role of microglia, correcting deficits in synaptic function and regulating oxidative stress response. The most advanced trofinetide program is for Rett syndrome, supported by rettsyndrome.org. Both the Rett syndrome and Fragile X syndrome programs have been granted Fast Track designation by the US Food and Drug Administration and have Orphan Drug designation in both the United States and the European Union. 2 of 2 Forward-looking Statements This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement. For more information, please contact: Dr Richard Treagus, Executive Chairman: [email protected]; +61 417 520 509

The release as fetched from its publisher. neurenpharma.com ↗